According to a new report from Intel Market Research, the global Durvalumab Market was valued at USD 1.85 billion in 2025 and is projected to grow from USD 2.12 billion in 2026 to USD 4.76 billion by 2034, exhibiting a robust CAGR of 10.6% during the forecast period. Growth is driven by increasing cancer prevalence, advancements in immuno-oncology research, and rising investments in targeted...
English
Indonesia
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek